<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_CSBJ1858 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEga1 jpg ?>
<?FILEmmc1 docx ?>
<?FILEmmc2 csv ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Comput Struct Biotechnol J</journal-id>
    <journal-id journal-id-type="iso-abbrev">Comput Struct Biotechnol J</journal-id>
    <journal-title-group>
      <journal-title>Computational and Structural Biotechnology Journal</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2001-0370</issn>
    <publisher>
      <publisher-name>Research Network of Computational and Structural Biotechnology</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9674861</article-id>
    <article-id pub-id-type="pii">S2001-0370(22)00504-9</article-id>
    <article-id pub-id-type="doi">10.1016/j.csbj.2022.11.010</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ProxyBind: A compendium of binding sites for proximity-induced pharmacology</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Rovers</surname>
          <given-names>Evianne</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Liu</surname>
          <given-names>Lihua</given-names>
        </name>
        <xref rid="af005" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Schapira</surname>
          <given-names>Matthieu</given-names>
        </name>
        <email>matthieu.schapira@utoronto.ca</email>
        <xref rid="af005" ref-type="aff">a</xref>
        <xref rid="af010" ref-type="aff">b</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="af005"><label>a</label>Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada</aff>
      <aff id="af010"><label>b</label>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding author at: Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada. <email>matthieu.schapira@utoronto.ca</email></corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>08</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>08</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>20</volume>
    <fpage>6163</fpage>
    <lpage>6171</lpage>
    <history>
      <date date-type="received">
        <day>23</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>4</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>4</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 The Authors</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract abstract-type="graphical" id="ab005">
      <title>Graphical abstract</title>
      <fig id="f0025" position="anchor">
        <graphic xlink:href="ga1"/>
      </fig>
    </abstract>
    <abstract id="ab010">
      <p>Proximity-induced pharmacology (ProxPharm) is a novel paradigm in drug discovery where a small molecule brings two proteins in close proximity to elicit a signal, generally from one protein onto another. The potential of ProxPharm compounds as a new therapeutic modality is firmly established by proteolysis targeting chimeras (PROTACs) that bring an E3 ubiquitin ligase in proximity to a target protein to induce ubiquitination and subsequent degradation of the target. The concept can be expanded to induce other post-translational modifications via the recruitment of different types of protein-modifying enzymes. To survey the human proteome for opportunities in proximity pharmacology, we systematically mapped non-catalytic drug binding pockets on the structure of protein-modifying enzymes available from the Protein Databank. In addition to binding sites exploited by previously reported ProxPharm compounds, we identified putative ligandable non-catalytic pockets in 236 kinases, 45 phosphatases, 37 deubiquitinases, 14 methyltransferases, 11 acetyltransferases, 13 glycosyltransferases, 4 deacetylases, 7 demethylases and 2 glycosidases, including cavities occupied by chemical matter that may serve as starting points for future ProxPharm compounds. This systematic survey confirms that proximity pharmacology is a versatile modality with largely unexplored and promising potential and reveals novel opportunities to pharmacologically rewire molecular circuitries. All data is available from the ProxyBind database at <ext-link ext-link-type="uri" xlink:href="https://polymorph.sgc.utoronto.ca/proxybind/index.php" id="ir005">https://polymorph.sgc.utoronto.ca/proxybind/index.php</ext-link>.</p>
    </abstract>
    <kwd-group id="kg005">
      <title>Keywords</title>
      <kwd>PROTAC</kwd>
      <kwd>Proteome</kwd>
      <kwd>Proximity pharmacology</kwd>
      <kwd>Kinases</kwd>
      <kwd>Phosphatases</kwd>
      <kwd>Post-translational modification</kwd>
    </kwd-group>
    <kwd-group id="pc_UzshqCdZdz6yUhAOHNmbTgCFaBpX40my">
      <title>Abbreviations</title>
      <kwd>ProxPharm, Proximity Pharmacology</kwd>
      <kwd>PROTAC, Proteolysis Targeting Chimera</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s0005">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0005">Proteolysis targeting chimeras (PROTACs) are bifunctional small molecules that simultaneously bind an E3 ubiquitin ligase and a target protein, thereby inducing the ubiquitination and subsequent proteasomal degradation of the protein target <xref rid="b0005" ref-type="bibr">[1]</xref>. This type of molecules has evolved over the past 20 years from a chemical biology curiosity to a promising therapeutic modality, with clear dose-dependent degradation of therapeutic targets such as AR, IRAK4 or BTK observed in man (clinicaltrials.gov identifiers NCT03888612, NCT04772885, NCT04830137), and the question is no longer whether but when the first PROTAC will be approved for therapeutic use by regulatory agencies. Proximity-induced Pharmacology (ProxPharm) is an extension of targeted protein degradation, where chemically induced proximity with proteins beyond E3 ligases can be used to rewire the molecular circuitry of cells for chemical biology applications or therapeutic benefit <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>. Indeed, ProxPharm compounds were recently reported that recruit a phosphatase, two kinases, an acetyltransferase, and a deubiquitinase to post-translationally modify neosubstrates <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>.</p>
    <p id="p0010">Structural studies have shown that PROTACs are not simply acting as chemical linkers but rather stabilize non-natural protein–protein interactions between E3 ligases and target proteins <xref rid="b0040" ref-type="bibr">[8]</xref>. Because compatible protein interfaces do not always exist between two proteins, a prevailing notion is that a collection of chemical handles binding a diverse array of E3 ligases will be necessary to productively induce the degradation of any given protein. Additionally, the tissue expression profile and subcellular localization of the E3 ligase must match that of the target protein for a PROTAC to be active. Finally, PROTACs recruiting E3 ligases with disease-specific tissue expression profiles can avoid adverse effects associated with the indiscriminate inhibition of the protein target. For example, a senolytic PROTAC exploits the restricted expression profile of the E3 ligase CRBN to avoid toxicity associated with the adverse inhibition of the target protein, Bcl-xl, in platelets <xref rid="b0045" ref-type="bibr">[9]</xref>. Similar rules are expected to apply to ProxPharm compounds beyond PROTACs, emphasizing the need to identify chemical handles for a diverse array of protein-modifying enzymes.</p>
    <p id="p0015">To uncover novel opportunities for the development of future ProxPharm compounds, we searched for non-catalytic ligandable pockets (structural cavities that can be occupied by small-molecule ligands) in all experimental structures of human protein-modifying enzymes, including kinases, phosphatases, acetyltransferases, deacetylases, methyltransferases, demethylases, glycosyltransferases, glycosidases and deubiquitinases. These pockets need to be non-catalytic to preserve the catalytic activity of the protein-modifying enzyme which is necessary for the ProxPharm-induced response. The ligandability of E3 ligases was previously reviewed and not considered in this analysis which is focused on opportunities for proximity pharmacology beyond PROTACs <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>. We identified non-catalytic pockets in 369 human enzymes, including those recruited by previously reported ProxPharm compounds. This analysis further confirms the rich potential of proximity pharmacology for chemical biology applications.</p>
  </sec>
  <sec id="s0010">
    <label>2</label>
    <title>Methods</title>
    <sec id="s0015">
      <label>2.1</label>
      <title>Mapping binding pockets</title>
      <p id="p0020">A list of enzymes was compiled from the Expasy ENZYME database and the UniprotKB database <xref rid="b0075" ref-type="bibr">[15]</xref> and mapped to corresponding PDB codes. The 3D structures were extracted from the PDB and the biologically relevant oligomeric state was generated with ICM (Molsoft, San Diego). The icmPocketfinder module was run against each converted ICM object using default settings. The pockets were categorized as non-catalytic based on the following two approaches.</p>
    </sec>
    <sec id="s0020">
      <label>2.2</label>
      <title>Interpro domain analysis</title>
      <p id="p0025">The domain architecture of each enzyme was extracted from the InterPro database <xref rid="b0080" ref-type="bibr">[16]</xref>. The domains were marked either as catalytic or non-catalytic based on GO ontology or literature. Residues within 2.8 Å of the pocket mesh generated by ICM were considered as lining the pocket, and the N- and C-terminal boundaries of this selection were used to define a ‘pseudo’ sequence for the pocket. These sequences were aligned and compared with the domain architecture of the enzyme to determine the domain location of the pocket. If the pocket was in a manually curated non-catalytic domain, the pocket was marked non-catalytic.</p>
    </sec>
    <sec id="s0025">
      <label>2.3</label>
      <title>Catalytic residues proximity analysis</title>
      <p id="p0030">For each enzyme, the corresponding catalytic residue information was extracted from either the Mechanism and Catalytic Site Atlas database <xref rid="b0085" ref-type="bibr">[17]</xref> or UniprotKB database <xref rid="b0075" ref-type="bibr">[15]</xref>. If the catalytic residues were present in the structure, the distance between the pockets and the catalytic residues were measured. If the pocket was more than 7 Å away from the catalytic residues, it was categorized as non-catalytic.</p>
    </sec>
    <sec id="s0030">
      <label>2.4</label>
      <title>Additional filters</title>
      <p id="p0035">Nucleotide binding residues and co-factor binding residues information was extracted from the UniprotKB database to determine which pockets corresponded to nucleotide or co-factor binding sites. For example, the ATP binding site in protein kinases or the acetyl-CoA binding site in acetyltransferases. If the distance between the pocket and nucleotide/co-factor binding residues was&lt;7 Å, the pocket was filtered out. If the pocket was in proximity (&lt;5Å) of unresolved residues in the structure due to poor electron density, the pocket was not included for further analysis. If the catalytic residues were among the missing residues, pockets were excluded as well. Pockets were also excluded when located at the interface of inhibitor proteins and enzyme complexes. Next, pockets were filtered for duplicates: when two structures representing the same enzyme had a similar pocket, the largest pocket was retained. Pockets predicted unligandable were also removed: ligandability was determined using the pocket properties generated by ICM (volume: 155.7–661.1 Å3, area: 155–655 Å2, hydrophobicity: &gt;0.44, buriedness: 0.6–0.95, DLID <xref rid="b0090" ref-type="bibr">[18]</xref>: &gt;-1). Cut-off values were based on properties of experimentally proven druggable pockets. Lastly, the pockets were grouped based on their domains. A list of manually curated non-catalytic domains was formed, from which non-catalytic domains necessary for the catalytic activity were excluded.</p>
    </sec>
    <sec id="s0035">
      <label>2.5</label>
      <title>Cysteine reactivity</title>
      <p id="p0040">The predicted reactivity of cysteine sidechains lining pockets was predicted using the ReactiveCys module of ICM. The method is based on reactivity data for 34 reactive and 184 non-reactive cysteines from isoTOP-ABPP (isotopic tandem orthogonal proteolysis activity-based protein profiling) <xref rid="b0095" ref-type="bibr">[19]</xref> and a nonredundant set of PDB protein structures (resolution &lt; 2.5 A) with covalently-modified cysteines (272 reactive).</p>
    </sec>
  </sec>
  <sec id="s0040">
    <label>3</label>
    <title>Results</title>
    <p id="p0045">To assemble a database of druggable binding pockets that may be exploited by ProxPharm compounds, all high-resolution structures of human protein-modifying enzymes beyond E3 ligases in the PDB were analyzed with the cavity mapping tool IcmPocketFinder (Molsoft, San Diego). Only structural cavities with properties (volume, area, hydrophobicity, buriedness and drug-like density (DLID)) within a pre-defined range (detailed in the Methods section) were deemed ligandable and were considered further. A permissive definition of ligandability was used to reflect the fact that chemical handles for ProxPharm compounds do not need to bind with high potency to their target. Indeed, ligands with up to 10 µM affinity have been successfully used to make PROTACs <xref rid="b0100" ref-type="bibr">[20]</xref>. When a ligandable cavity was found in a non-catalytic domain, the domain was also deemed ligandable in the context of enzymes not in the PDB, but with a low confidence score. When enzymes were bound to other proteins in the PDB, cavities were also searched at the protein interface. Pockets that may be exploited by ProxPharm compounds could be divided into three categories: 1) those located in non-catalytic domains, 2) those found at non-catalytic sites of the catalytic domain, 3) those mapping at the interface of protein complexes (<xref rid="f0005" ref-type="fig">Fig. 1</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>Distribution of non-catalytic pockets in human protein-modifying enzymes. The number of proteins with a putative ligandable non-catalytic pocket is shown for each structural domain and each protein family. For each enzyme family, the total number of proteins in human can be found in <xref rid="s0120" ref-type="sec">Table S1</xref>.</p></caption><graphic xlink:href="gr1"/></fig></p>
    <p id="p0050">Potentially ligandable non-catalytic pockets were found in 236 kinases, 45 phosphatases, 37 deubiquitinases, as well as several writers and erasers of methyl, acetyl and glycosyl groups (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S1-3</xref>). In the following section, we review in detail each protein family.</p>
    <sec id="s0045">
      <label>3.1</label>
      <title>Protein kinases</title>
      <p id="p0055">Ligandable non-catalytic pockets were found in the catalytic domain of 170 kinases (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>). For instance, in 86 kinases, a pocket is found in the α-lobe of the kinase domain (<xref rid="f0010" ref-type="fig">Fig. 2</xref>A, Pocket PK3) and, in the context of Abelson kinase, is exploited by an activating compound located over 15 Å away from the imatinib-occupied active site (<xref rid="s0120" ref-type="sec">Figure S1</xref>, PDB 6NPU, Pocket PK3) <xref rid="b0105" ref-type="bibr">[21]</xref>. Other pockets are recurrently found at five other locations and could potentially be exploited to pharmacologically hijack kinases (<xref rid="s0120" ref-type="sec">Figure S1</xref>). In particular, 47 kinases share a cavity below the sub-activation loop (<xref rid="s0120" ref-type="sec">Figure S1</xref>, Pocket PK4) which is occupied by a small molecule in the MAP kinase p38α <xref rid="b0110" ref-type="bibr">[22]</xref> (PDB 3HVC). A β-lobe cavity is found in another 25 kinases (<xref rid="s0120" ref-type="sec">Figure S1</xref>, Pocket PK5), where, in PDK1, a cysteine is covalently engaged by fragment inhibitors or activators (PDB 3ORZ) <xref rid="b0115" ref-type="bibr">[23]</xref> and a different β-lobe pocket is identified in 9 kinases (<xref rid="s0120" ref-type="sec">Figure S1</xref>, Pocket PK2) and occupied by a fragment molecule in the context of CDK2 (PDB 6Q4D) <xref rid="b0120" ref-type="bibr">[24]</xref>.<fig id="f0010"><label>Fig. 2</label><caption><p>Recurrent non-catalytic pockets found in kinases. A) Pockets found in the kinase domain. ABL1 (blue) bound to catalytic inhibitor (orange) is used as a canonical reference structure (PDB: 6NPU <xref rid="b0105" ref-type="bibr">[21]</xref>). An allosteric activator is shown in purple. A similar pocket is found in 86 protein kinases. B) Phorbol ester bound to the C1 domain of KPCD (PDB: 1PTR <xref rid="b0140" ref-type="bibr">[28]</xref>). A C1 domain can be found in 23 protein kinases. Benzolactam binds to C1 domains and is used as chemical handle to recruit protein kinase C (type delta) to Bromodomain-containing protein 4 (PHICS2) <xref rid="b0020" ref-type="bibr">[4]</xref>. The full list of kinases and pockets summarized here is provided in <xref rid="s0120" ref-type="sec">Table S2, S3</xref> and in the database ProxyBind.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0060">Ligandable pockets were also found at the interface of the catalytic domain of 3 kinases (PRKAA1, PRKAA2, CDK5) and cofactor proteins (<xref rid="s0120" ref-type="sec">Figure S1</xref>). For example, a pharmacological activator is sandwiched at the interface of the β-lobe of PRKAA1 and its cofactor PRKAB1 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>B, Pocket PKI1) <xref rid="b0125" ref-type="bibr">[25]</xref>. Interestingly, this chemical scaffold was recently linked to an inhibitor of Bruton’s tyrosine kinase (BTK), leading to the phosphorylation of BTK by PRKAA1 in cells, in what was the first example of a phosphorylation-inducing chimeric small molecule (PHIC) <xref rid="b0020" ref-type="bibr">[4]</xref>. Another pocket is found at the interface of CDK5 and CDK5R1, a neural-specific CDK5 activator protein, raising the possibility to develop brain-specific phosphorylating agents that would exploit this site (<xref rid="s0120" ref-type="sec">Figure S1</xref>).</p>
      <p id="p0065">Multiple potentially ligandable cavities were also identified in non-catalytic domains of kinases (<xref rid="s0120" ref-type="sec">Table S2</xref>, <xref rid="s0120" ref-type="sec">Figure S2</xref>). For example, a cavity was found in the non-catalytic C1 domain of 23 kinases such as BRAF, CDC42 binding kinases, or PKC kinases (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). Binding of diacylglycerol to this pocket leads to translocation from the cytosol to the membrane of PKC kinases, and catalytic activation <xref rid="b0130" ref-type="bibr">[26]</xref>. The cavity was successfully targeted by drug-like molecules such as V8-benzolactams <xref rid="b0135" ref-type="bibr">[27]</xref>, which can be used as PKC-recruiting handles in heterobifunctional PHICS. Using this strategy, Siriwardena et al. could induce the phosphorylation of BRD4 by PKC <xref rid="b0020" ref-type="bibr">[4]</xref>. A similar strategy may be applied to the other kinases where we also identified a C1-domain cavity.</p>
      <p id="p0070">A membrane-targeting C2 domain is also present in 6 protein kinases, including PKC kinases, but the ligandability of its phosphatidylserine binding pocket is unclear. A tyrosine-lined pocket conserved in the POLO domain of PLK kinases participates in substrate recognition and was targeted by weak compounds that would need to be optimized to serve as ProxPharm handles (<xref rid="s0120" ref-type="sec">Figure S2</xref>) <xref rid="b0145" ref-type="bibr">[29]</xref>. Five kinases contain a WD-40 repeat (WDR), which is a β -propeller domain with a druggable central cavity <xref rid="b0150" ref-type="bibr">[30]</xref>. For instance, the WDR domain of LRRK2 could be exploited by future PHICS to phosphorylate targets in the brain, where it is expressed.</p>
      <p id="p0075">Other protein domains of potential interest were identified in human kinases, but even though cavities meeting our selection criteria were found, the general ligandability of these domains remains to be supported experimentally. For instance, 29 kinases contain an immunoglobulin-like domain (<xref rid="f0005" ref-type="fig">Figure 1</xref> and <xref rid="s0120" ref-type="sec">S2</xref>). Small molecule ligands were shown to bind to the immunoglobulin-like domain of the unrelated protein RAGE, but ligands were prohibitively weak <xref rid="b0155" ref-type="bibr">[31]</xref>. Another 28 kinases contain both SH2 and SH3 domains (<xref rid="f0005" ref-type="fig">Figure 1</xref> and <xref rid="s0120" ref-type="sec">S2</xref>), known to participate in the formation of an auto-inhibitory state and contribute to substrate recruitment of Src family kinases. Despite sustained efforts, potent, drug- like, cell-penetrant ligands remain to be found for these domains. Nevertheless, they may be sufficiently ligandable for the discovery of weak compounds that may serve as valid chemical handles for kinase-recruiting ProxPharm molecules. In another example, the poorly characterized kinase STK31 includes a Tudor domain (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>), generally found in proteins involved in chromatin-mediated signaling. This domain was targeted by a potent chemical probe in the context of the methyltransferase SETDB1 <xref rid="b0160" ref-type="bibr">[32]</xref> and may be ligandable in STK31.</p>
    </sec>
    <sec id="s0050">
      <label>3.2</label>
      <title>Protein phosphatases</title>
      <p id="p0080">Non-catalytic pockets were found in 51 protein phosphatases (<xref rid="s0120" ref-type="sec">Table S3</xref>). Among these, 38 protein phosphatases have a non-catalytic pocket in the catalytic domain and 20 enzymes in juxtaposed domains (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>). Some of the non-catalytic cavities were recurrently found in the phosphatase domain: 13 tyrosine-protein phosphatases share a cavity 15 Å from the catalytic site (<xref rid="f0015" ref-type="fig">Fig. 3</xref>, Pocket PP3), which, in the context of PTPN5, is occupied by an allosteric activator (PDB 6H8R) <xref rid="b0165" ref-type="bibr">[33]</xref>. The recurrent pocket locations are labelled as pocket Protein Phosphatase # (Pocket PP#). Other recurrent cavities are found at four other locations of the catalytic domain and could potentially be exploited to recruit tyrosine-protein phosphatases to target proteins (<xref rid="f0015" ref-type="fig">Fig. S3</xref>A). Furthermore, 5 serine/threonine-protein phosphatases have 4 recurrent non-catalytic cavities in their catalytic domain (<xref rid="f0015" ref-type="fig">Fig. S3</xref>B).<fig id="f0015"><label>Fig. 3</label><caption><p>Recurrent non-catalytic pockets mapping at protein phosphatase domains. A) Pocket in the catalytic domain of tyrosine-protein phosphatases 5 bound to an allosteric activator (purple) 15 Å from the catalytic site (PDB 6H8R). A similar pocket (labelled PP3 in Table S3 and the Proxybind database) is recurrent in 14 tyrosine-protein phosphatases. B) Pocket found at the interface of the protein phosphatase 2A catalytic domain (gray) and interacting subunits (blue and yellow) with allosteric activator (PDB: 6NTS) <xref rid="b0170" ref-type="bibr">[34]</xref>.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0085">Non-catalytic pockets were also found at multiple protein–protein interfaces (locations denoted as Pocket Protein Phosphatases Interface # (Pocket PPI#)), including a cavity located at the interface of the three subunits of the protein phosphatase 2A (PP2A) heterotrimer, and occupied by a small molecule activator <xref rid="b0170" ref-type="bibr">[34]</xref> (<xref rid="f0015" ref-type="fig">Fig. 3</xref>, Pocket PPI1, <xref rid="s0120" ref-type="sec">Figure S4</xref>). Heterobifunctional compounds derived from this activator could potentially be used for targeted dephosphorylation. This hypothesis is further supported by the fact that another phosphatase, PP2A, was successfully recruited to dephosphorylate the kinases AKT or EGFR by linking kinase inhibitors to peptidic ligands that exploit the tetratricopeptide repeat domain in PP2A <xref rid="b0025" ref-type="bibr">[5]</xref>.</p>
      <p id="p0090">Cavities are also found in the PDZ domain of protein phosphatases PTPN3, PTPN4 and PTPN14 (<xref rid="s0120" ref-type="sec">Figure S5</xref>). The ligandability of these pockets is not experimentally validated, but they are occupied by the C-terminal leucine or valine of pentameric peptide ligands <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, and a similar pocket in the PDZ domain of the unrelated protein PICK1 was crystallized in complex with a small molecule binding with sub-micromolar potency <xref rid="b0185" ref-type="bibr">[37]</xref>. Finally, pockets with unclear ligandability were found in the SH2 domain of phosphatases PTPN6, PTPN11 and TNS2, and the tetratricopeptide repeat of PPP5C (<xref rid="s0120" ref-type="sec">Figure S5</xref>).</p>
    </sec>
    <sec id="s0055">
      <label>3.3</label>
      <title>Protein methyltransferases</title>
      <p id="p0095">Protein methyltransferases (PMTs) are typically large multi-modular proteins where chromatin-binding binding modules are often found juxtaposed to the catalytic domain. For instance, a PWWP domain is found in the NSD subfamily of PMTs (NSD1, NSD2 and NSD3) and chemical probes were reported for the PWWP domain of NSD2 and NSD3 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0195" ref-type="bibr">[39]</xref>. The NSD3 ligand was recently used as the chemical handle of an NSD3-degrading PROTAC <xref rid="b0200" ref-type="bibr">[40]</xref>. These ligands - which do not inhibit the enzymatic activity – could also potentially serve as chemical moieties to recruit NSD2 or NSD3 for the methylation of new protein substrates.<fig id="f0020"><label>Fig. 4</label><caption><p>Examples of pockets in non-catalytic domains of methyltransferases, acetyltransferases, demethylases, deacetylases and deubiquitinases. PWWP domain in NSD2 with small-molecule ligand (PDB: 6UE6 <xref rid="b0275" ref-type="bibr">[55]</xref>), bromodomain in EP300 with small-molecule ligand (PDB: 5BT3), Tudor domain in SETDB1 with small-molecule ligand (PDB: 7CJT <xref rid="b0160" ref-type="bibr">[32]</xref>), zinc-finger, UBP-type in HDAC6 with small-molecule ligand (PDB: 5KH7 <xref rid="b0280" ref-type="bibr">[56]</xref>), Tudor domain in KDM4A with chemical fragment (PDB: 5VAR <xref rid="b0230" ref-type="bibr">[46]</xref>), ZnF-UBD in USP5 with small-molecule ligand (PDB: 6DXT <xref rid="b0255" ref-type="bibr">[51]</xref>).</p></caption><graphic xlink:href="gr4"/></fig></p>
      <p id="p0100">SETDB1, another multi-modular PMT, includes a non-catalytic Tudor domain selectively targeted by a potent chemical probe that may be linked to other ligands to methylate non-natural protein substrates (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) <xref rid="b0160" ref-type="bibr">[32]</xref>. Interestingly, recurrent genetic aberrations drive the overexpression of NSD2 in multiple myeloma and pediatric leukemia, and of NSD2, NSD3 and SETDB1 in lung cancer <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0220" ref-type="bibr">[44]</xref>, which could possibly offer an opportunity for targeted protein methylation in cells presenting a specific disease-associated genetic profile. Putative ligandable cavities were found in a few other non-catalytic domains of PMTs, including the bromodomain of KMT2A and ASH1L (bromodomains are typically druggable (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) <xref rid="b0225" ref-type="bibr">[45]</xref>, but no ligand was reported for these domains.</p>
      <p id="p0105">A recurrent pocket was also found in the catalytic domain of two protein arginine methyltransferases, PRMT3 and PRMT8, which is located more than 17 Å away from the catalytic site (<xref rid="s0120" ref-type="sec">Figure S6</xref>, Pocket M1). Other unique non-catalytic pockets were found in the methyltransferase catalytic domain of 3 PMTs (PRMT3, SETD7, CARM1) (<xref rid="s0120" ref-type="sec">Table S3</xref>). These cavities met our ligandability criteria but so far, their chemical tractability was not validated experimentally.</p>
    </sec>
    <sec id="s0060">
      <label>3.4</label>
      <title>Lysine demethylases</title>
      <p id="p0110">A number of non-catalytic domains of lysine demethylases include potentially ligandable pockets. KDM4A, KDM4B and KDM4C all have a Tudor domain, which was shown to be chemically tractable in the context of SETDB1. The Tudor domain of KDM4A was crystallized in complex with a low-affinity chemical fragment (K<sub>D</sub> ∼ 80 µM) that may be optimized into a stronger-binding chemical handle towards the development of a demethylase-recruiting bifunctional molecules (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) <xref rid="b0230" ref-type="bibr">[46]</xref>. Putative ligandable pockets were also found in the tetratricopeptide repeat of KDM6A and UTY and the SWIRM domain of KDM1A and KDM1B (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>), but no ligand was so far reported for these domains.</p>
    </sec>
    <sec id="s0065">
      <label>3.5</label>
      <title>Lysine acetyltransferases</title>
      <p id="p0115">With over 3000 acetylated lysine sidechains across 1700 human proteins, acetylation is a ubiquitous post-translational modification involved in a diverse array of cellular machineries such as the regulation of gene expression, splicing or cell cycle <xref rid="b0235" ref-type="bibr">[47]</xref>, <xref rid="b0240" ref-type="bibr">[48]</xref>. Out of 35 lysine acetyltransferases in the human genome, we found non-catalytic ligandable pockets in 9 (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S3</xref>). Several acetyltransferases include an acetyl-lysine binding bromodomain, five of which were crystallized in complex with multiple small-molecule ligands (EP300, CREBBP, KAT2A, KAT2B and TAF1) (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) <xref rid="b0225" ref-type="bibr">[45]</xref>. A compound targeting the bromodomain of one of these, EP300, was chemically linked to an FKBP12-binding molecule to successfully induce the acetylation of FKBP12-fusion proteins by EP300, thereby confirming that acetyltransferases are amenable to proximity pharmacology, and strongly suggesting that bromodomain ligands could be used as chemical handles to recruit other acetyltransferases to neosubstrates <xref rid="b0035" ref-type="bibr">[7]</xref>.</p>
      <p id="p0120">A WDR domain is also found in GTF3C4, a poorly characterized acetyltransferase (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>). The structure of this domain was not experimentally solved, but WDR domains are ligandable in the context of other proteins <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref> and this enzyme could potentially be harnessed for targeted acetylation.</p>
    </sec>
    <sec id="s0070">
      <label>3.6</label>
      <title>Lysine deacetylases</title>
      <p id="p0125">Deacetylases have a limited number of non-catalytic domains and a ligandable site was found in only one of them: the zinc-finger ubiquitin-binding domain (Znf-UBD) of HDAC6 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). This binding pocket recognizes the C-terminal extremity of ubiquitin and was successfully targeted by small molecule ligands <xref rid="b0250" ref-type="bibr">[50]</xref> representing excellent chemical handles for proximity pharmacology applications. Non-catalytic pockets were also found in the catalytic domain of three other deacetylases: HDAC4, HDAC8 and HDAC1, but the ligandability of these sites remains to be experimentally validated (<xref rid="s0120" ref-type="sec">Figure S7</xref>).</p>
    </sec>
    <sec id="s0075">
      <label>3.7</label>
      <title>Deubiquitinases</title>
      <p id="p0130">Deubiquitinases (DUBs) typically remove ubiquitin tags deposited by E3 ligases. When these tags are signalling for proteasomal degradation, DUBs deubiquitinate and rescue their protein substrates from the ubiquitin–proteasome system and have a stabilizing effect on their target. Chemical handles binding non-catalytic pockets of DUBs may therefore enable the recruitment of DUBs for targeted protein stabilization. As a proof-of-concept, a bifunctional molecule linking a ligand that covalently engages the DUB OTUB1 to a chemical moiety that binds ΔF508-CFTR in cystic fibrosis could stabilize ΔF508-CFTR in an OTUB1-dependent manner <xref rid="b0030" ref-type="bibr">[6]</xref>. There is no structural information on the <italic>N</italic>-terminal domain of OTUB1 that is covalently recruited by this chimeric compound, but structures of other non-catalytic domains in DUBs reveal other opportunities for targeted protein stabilization.</p>
      <p id="p0135">The most recurrent ligandable non-catalytic domain of DUBs is the Znf-UBD, found in 12 ubiquitin-specific proteases (USPs, a class of DUBs) (<xref rid="s0120" ref-type="sec">Figure S7</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>). Low micromolar ligands were reported for the Znf-UBD of USP5, but these compounds were shown to inhibit the catalytic activity of USP5 and therefore cannot be used as chemical handles to productively recruit USP5 to neosubstrates <xref rid="b0255" ref-type="bibr">[51]</xref>. However, the function of the Znf-UBD of DUBs is poorly understood in other USPs, and ligands targeting this domain may still be valid handles for targeted protein stabilization in the context of other DUBs.</p>
      <p id="p0140">Ligandable pockets were also found in a tandem ubiquitin-like domain located at the C-terminus of four DUBs: USP7, 11, 15 and 25 (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="s0120" ref-type="sec">Table S2</xref>). In the context of USP7, this domain binds and activates the catalytic domain <xref rid="b0260" ref-type="bibr">[52]</xref>. In the absence of structure of full-length USP7 in its activated form, it is unclear whether ligands occupying this C-terminal binding pocket would preserve the activation mechanism of USP7 and could be used to productively recruit USP7 for targeted protein stabilization. Another non-catalytic domain present in deubiquitinases is a SWIRM domain in MYSM1. Chemical ligands have not yet been reported for this domain. Non-catalytic pockets were recurring at six locations of eight USPs within the peptidase C19-type catalytic domain (<xref rid="s0120" ref-type="sec">Figure S8</xref>A, <xref rid="s0120" ref-type="sec">Table S3</xref>). Another non-catalytic cavity is observed in the peptidase C12-type catalytic domain of UCHL1 and UCHL5 (<xref rid="s0120" ref-type="sec">Figure S8</xref>B, <xref rid="s0120" ref-type="sec">Table S3</xref>). As above, the ligandability of these pockets needs to be confirmed experimentally.</p>
    </sec>
    <sec id="s0080">
      <label>3.8</label>
      <title>Glycosyltransferases</title>
      <p id="p0145">Glycosylation is a post-translational modification that is most common in excreted and extracellular membrane-associated proteins and is frequently dysregulated in diseases, such as cancer or bacterial infection <xref rid="b0265" ref-type="bibr">[53]</xref>. Proof of principle for proximity-induced glycosylation of target proteins was established by fusing substrate-targeting nanobodies to the glycosyltransferase O-GlcNActransferase (OGT), which effectively induced the glycosylation of the desired protein targets <xref rid="b0270" ref-type="bibr">[54]</xref>. Putative ligandable pockets in the tetratricopeptide repeat of OGT and TMTC1-4 may be exploited to chemically recruit these glycosyltransferases to neosubstrates. Similarly, the SH3 domain of FUT8 and WW domain of GALNT9 may be considered for the chemical recruitment of these enzymes. Non-catalytic cavities in the glycosyltransferase domain of ST8SIA3, B3GAT1-3, and POFUT2 were also found but, as above, their ligandability should be confirmed experimentally.</p>
    </sec>
    <sec id="s0085">
      <label>3.9</label>
      <title>Glycosidases</title>
      <p id="p0150">Similar to glycosyltransferases, protein constructs have been developed using O-GlcNAcase or sialidase connected to nanobody to artificially induce deglycosylation <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>. There are limited structures and domain information available for glycosidases, but ligandable pockets are found in the catalytic domain of OGA and MAN1B1 that could be explored for deglycosylation-inducing chimeras.</p>
    </sec>
    <sec id="s0090">
      <label>3.10</label>
      <title>Reactive cysteines</title>
      <p id="p0155">PROTACs covalently engaging an E3-ligase have demonstrated that covalent binding is a valid strategy for proximity-induced post-translational modification of target proteins <xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>. For instance, covalent recruitment of only a small fraction of the cellular pool of the E3-ligase DCAF16 is sufficient to support targeted degradation <xref rid="b0305" ref-type="bibr">[61]</xref>. A deubiquitinase-targeting chimera also forms a covalent bond with a cysteine of the DUB OTUB1 <xref rid="b0030" ref-type="bibr">[6]</xref>. Electrophilic chemical handles enable the covalent recruitment of domains otherwise not considered ligandable, such as the RING domain of the E3-ligase RNF4 <xref rid="b0300" ref-type="bibr">[60]</xref>, and can be advantageous to enhance potency or selectivity. We used ICM to evaluate the reactivity of cysteine sidechains found in non-catalytic pockets of human protein-modifying enzymes (see Methods section for details).</p>
      <p id="p0160">Reactive cysteines were predicted in multiple proteins (<xref rid="s0120" ref-type="sec">Figure S9</xref>, <xref rid="s0120" ref-type="sec">Table S3</xref>). For instance, C576 is lining a pocket in the UBL domain of USP7 C-terminal to the catalytic domain, C210 is found at an ectopic site of the STK16 kinase domain, C266 at a non-catalytic site of the PP2BA phosphatase domain, and C1030 at a cavity remote from the active site of the deacetylase HDAC4 (<xref rid="s0120" ref-type="sec">Figure S9</xref>). It would be interesting to screen such proteins with electrophilic fragments to find covalent adducts that may serve as a starting point for novel proximity-pharmacology applications.</p>
    </sec>
  </sec>
  <sec id="s0095">
    <label>4</label>
    <title>Discussion</title>
    <p id="p0165">Our systematic structural survey of the human proteome reveals numerous opportunities for the pharmacological recruitment of protein-modifying enzymes beyond E3 ligases to non-natural substrates. The predicted ligandability of a binding pocket can vary from one method to another and is not a conclusive metric. Here, we use a permissive definition based on volume, area, hydrophobicity, buriedness and DLID values. We first note that, in addition to the hundreds of new pockets identified, this approach does retrieve binding sites for known ProxPharm compounds, including a protein–protein interface pocket used to recruit the kinase PRKAA (<xref rid="f0005" ref-type="fig">Fig. S1</xref>B, Pocket PKI1) <xref rid="b0020" ref-type="bibr">[4]</xref> and a bromodomain pocket used to recruit the acetyltransferase EP300 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) <xref rid="b0035" ref-type="bibr">[7]</xref>.</p>
    <p id="p0170">Among the collection of binding sites that we compiled, we assigned the highest confidence (confidence level 1, <xref rid="s0120" ref-type="sec">Table S3-4</xref>) to the ones for which a high-affinity ligand was already reported. Table with ligandability confidence scale can be found in the <xref rid="s0120" ref-type="sec">Supplementary information</xref> (<xref rid="s0120" ref-type="sec">Table S4</xref>). For instance, V8-benzolactams bind the C1 domain of protein kinase C (<xref rid="f0010" ref-type="fig">Fig. 2</xref>B) <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, UNC6934 binds the PWWP domain of NSD2 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>) <xref rid="b0195" ref-type="bibr">[39]</xref> and compound R734 binds a protein interface of the kinase AMPK (<xref rid="f0005" ref-type="fig">Fig. S1</xref>B) <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>. A number of non-catalytic pockets were also found that are targeted by weak ligands that may be valid starting points for the development of ProxPharm compounds (confidence level 2, <xref rid="s0120" ref-type="sec">Table S3-4</xref>). These include compounds and peptides found in the POLO-box domain of PLK1 (<xref rid="s0120" ref-type="sec">Figure S2</xref>) <xref rid="b0145" ref-type="bibr">[29]</xref> and the PDZ domain of PTPN3 (<xref rid="s0120" ref-type="sec">Figure S5</xref>) <xref rid="b0175" ref-type="bibr">[35]</xref>. Because ProxPharm compounds induce the formation of ternary complexes where direct protein–protein interactions contribute to the overall energy of the system, proximity-inducing compounds can be derived from chemical handles binding with relatively weak affinity (up to 10 µM or more) to their target (Han et al. 2019). Binding sites with this lower confidence level therefore remain of potential interest. Less reliable, but still promising are domains for which no ligand was reported in the context of the protein of interest, but that were shown to be chemically tractable in other proteins (confidence level 3, <xref rid="s0120" ref-type="sec">Table S3-4</xref>). For example, low nanomolar ligands targeting the WDR domains of EED and WDR5 are in pre-clinical <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref> or clinical development (EED clinicaltrials.gov identifier NCT02900651) and WDR domains are found in the kinases LRRK1, LRRK2, MET, MST1R, PIK3R4 and the acetyltransferase GTF3C4 (<xref rid="s0120" ref-type="sec">Table S2</xref>). Similarly, Tudor domains are found in demethylases (KDM4A, KDM4B, KDM4C) and protein kinase STK31 (<xref rid="s0120" ref-type="sec">Table S2</xref>), and share a canonical aromatic cage with the Tudor domain of SETDB1 targeted by a high-affinity ligand (K<sub>D</sub> 90 nM) <xref rid="b0160" ref-type="bibr">[32]</xref>. Finally, sites that meet our ligandability criteria but for which no ligands were found in the protein of interest or close homologues are less reliable (confidence level 4, <xref rid="s0120" ref-type="sec">Table S3-4</xref>).</p>
    <p id="p0175">A limitation of our analysis is that we focused exclusively on the structures of enzymes that add or remove chemical or peptidic tags to proteins. In the future, we believe it would be interesting to expand to other enzymes, such as proteases. Pockets in non-catalytic protein subunits of enzymatic complexes may also serve as starting points for ProxPharm development. Lastly, proteins without enzymatic activity, for example transcription factors, could be analyzed for ligandable pockets that could be recruited with ProxPharm compounds. While beyond the scope of this work, such studies could be undertaken using methodologies similar to the ones presented here. We also limited our approach to proteins (and homologs) with structural information in the protein databank, but recent breakthroughs in protein structure predictions <xref rid="b0340" ref-type="bibr">[68]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0350" ref-type="bibr">[70]</xref> may enable a future expansion of the analysis to the entire human proteome. Finally, the design of hetero-bifunctional molecules with favourable ADME profiles able to productively induce protein–protein interactions in a structural arrangement that allows enzymatic activity of one protein onto the other remains a challenging trial-and-error process. The necessary combinatorial synthesis of candidate molecules with varying chemical handles and linkers, and subsequent screening are non-trivial experimentally. Recent signs of progress in the rational design of PROTACs should nevertheless be noted <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0360" ref-type="bibr">[72]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0370" ref-type="bibr">[74]</xref>, <xref rid="b0375" ref-type="bibr">[75]</xref>.</p>
    <p id="p0180">In spite of these limitations, the compendium of binding sites – including some with chemical starting points - for proximity-induced pharmacology assembled here reveals a multitude of avenues to harness protein modifying enzymes involved in epigenetic mechanisms, splicing, protein homeostasis and other cellular machineries. For example, recruiting histone methyltransferases or acetyltransferases to specific genomic loci may up-regulate repressed genes, while targeted glycosylation may be a mechanism to control inflammatory and viral immune responses. Now that molecular proof-of-concept was established for a number of enzyme classes, it is the time to fully explore and test the boundaries of this promising modality for chemical biology and drug discovery applications.</p>
  </sec>
  <sec id="s0100">
    <title>CRediT authorship contribution statement</title>
    <p id="p0185"><bold>Evianne Rovers:</bold> Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review &amp; editing. <bold>Lihua Liu:</bold> Data curation, Visualization. <bold>Matthieu Schapira:</bold> Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – review &amp; editing.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Declaration of Competing Interest</title>
    <p id="p0190">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>Pettersson</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Crews</surname>
            <given-names>C.M.</given-names>
          </name>
        </person-group>
        <article-title>PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future</article-title>
        <source>Drug Discov Today Technol</source>
        <volume>31</volume>
        <year>2019</year>
        <fpage>15</fpage>
        <lpage>27</lpage>
        <pub-id pub-id-type="doi">10.1016/J.DDTEC.2019.01.002</pub-id>
        <pub-id pub-id-type="pmid">31200855</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Gerry</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Schreiber</surname>
            <given-names>S.L.</given-names>
          </name>
        </person-group>
        <article-title>Unifying principles of bifunctional, proximity-inducing small molecules</article-title>
        <source>Nat Chem Biol</source>
        <volume>16</volume>
        <year>2020</year>
        <fpage>369</fpage>
        <lpage>378</lpage>
        <pub-id pub-id-type="doi">10.1038/S41589-020-0469-1</pub-id>
        <pub-id pub-id-type="pmid">32198490</pub-id>
      </element-citation>
    </ref>
    <ref id="b0015">
      <label>3</label>
      <element-citation publication-type="journal" id="h0015">
        <person-group person-group-type="author">
          <name>
            <surname>Conway</surname>
            <given-names>S.J.</given-names>
          </name>
        </person-group>
        <article-title>Bifunctional Molecules beyond PROTACs</article-title>
        <source>J Med Chem</source>
        <volume>63</volume>
        <year>2020</year>
        <fpage>2802</fpage>
        <lpage>2806</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00293</pub-id>
        <pub-id pub-id-type="pmid">32157887</pub-id>
      </element-citation>
    </ref>
    <ref id="b0020">
      <label>4</label>
      <element-citation publication-type="journal" id="h0020">
        <person-group person-group-type="author">
          <name>
            <surname>Siriwardena</surname>
            <given-names>S.U.</given-names>
          </name>
          <name>
            <surname>Munkanatta Godage</surname>
            <given-names>D.N.P.</given-names>
          </name>
          <name>
            <surname>Shoba</surname>
            <given-names>V.M.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Phosphorylation-Inducing Chimeric Small Molecules</article-title>
        <source>J Am Chem Soc</source>
        <volume>142</volume>
        <year>2020</year>
        <fpage>14052</fpage>
        <lpage>14057</lpage>
        <pub-id pub-id-type="doi">10.1021/JACS.0C05537</pub-id>
        <pub-id pub-id-type="pmid">32787262</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>5</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Yamazoe</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Tom</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Heterobifunctional Molecules Induce Dephosphorylation of Kinases-A Proof of Concept Study</article-title>
        <source>J Med Chem</source>
        <volume>63</volume>
        <year>2020</year>
        <fpage>2807</fpage>
        <lpage>2813</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01167</pub-id>
        <pub-id pub-id-type="pmid">31874036</pub-id>
      </element-citation>
    </ref>
    <ref id="b0030">
      <label>6</label>
      <element-citation publication-type="journal" id="h0030">
        <person-group person-group-type="author">
          <name>
            <surname>Henning</surname>
            <given-names>N.J.</given-names>
          </name>
          <name>
            <surname>Boike</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Spradlin</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Ward</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Deubiquitinase-targeting chimeras for targeted protein stabilization</article-title>
        <source>Nat Chem Biol</source>
        <year>2022</year>
        <fpage>18</fpage>
        <pub-id pub-id-type="doi">10.1038/s41589-022-00971-2</pub-id>
        <pub-id pub-id-type="pmid">34811516</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>7</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>W.W.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L.Y.</given-names>
          </name>
          <name>
            <surname>Wozniak</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Jadhav</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>T.E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targeted Protein Acetylation in Cells Using Heterobifunctional Molecules</article-title>
        <source>J Am Chem Soc</source>
        <volume>143</volume>
        <year>2021</year>
        <fpage>16700</fpage>
        <lpage>16708</lpage>
        <pub-id pub-id-type="doi">10.1021/jacs.1c07850</pub-id>
        <pub-id pub-id-type="pmid">34592107</pub-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>8</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>Gadd</surname>
            <given-names>M.S.</given-names>
          </name>
          <name>
            <surname>Testa</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lucas</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>K.H.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Lamont</surname>
            <given-names>D.J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Structural basis of PROTAC cooperative recognition for selective protein degradation</article-title>
        <source>Nat Chem Biol</source>
        <volume>135</volume>
        <issue>13</issue>
        <year>2017</year>
        <fpage>514</fpage>
        <lpage>521</lpage>
        <pub-id pub-id-type="doi">10.1038/nchembio.2329</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>9</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>He</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>H.-N.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity</article-title>
        <source>Nat Commun</source>
        <volume>11</volume>
        <year>2020</year>
        <fpage>1996</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-020-15838-0</pub-id>
        <pub-id pub-id-type="pmid">32332723</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>10</label>
      <element-citation publication-type="journal" id="h0050">
        <person-group person-group-type="author">
          <name>
            <surname>Schneider</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Radoux</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Hercules</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ochoa</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Dunham</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Zalmas</surname>
            <given-names>L.P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The PROTACtable genome</article-title>
        <source>Nat Rev Drug Discov</source>
        <volume>20</volume>
        <year>2021</year>
        <fpage>789</fpage>
        <lpage>797</lpage>
        <pub-id pub-id-type="doi">10.1038/S41573-021-00245-X</pub-id>
        <pub-id pub-id-type="pmid">34285415</pub-id>
      </element-citation>
    </ref>
    <ref id="b0055">
      <label>11</label>
      <element-citation publication-type="journal" id="h0055">
        <person-group person-group-type="author">
          <name>
            <surname>Schapira</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Calabrese</surname>
            <given-names>M.F.</given-names>
          </name>
          <name>
            <surname>Bullock</surname>
            <given-names>A.N.</given-names>
          </name>
          <name>
            <surname>Crews</surname>
            <given-names>C.M.</given-names>
          </name>
        </person-group>
        <article-title>Targeted protein degradation: expanding the toolbox</article-title>
        <source>Nat Rev Drug Discov</source>
        <volume>18</volume>
        <year>2019</year>
        <fpage>949</fpage>
        <lpage>963</lpage>
        <pub-id pub-id-type="doi">10.1038/S41573-019-0047-Y</pub-id>
        <pub-id pub-id-type="pmid">31666732</pub-id>
      </element-citation>
    </ref>
    <ref id="b0060">
      <label>12</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>Nalawansha</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Crews</surname>
            <given-names>C.M.</given-names>
          </name>
        </person-group>
        <article-title>PROTACs: An Emerging Therapeutic Modality in Precision Medicine</article-title>
        <source>Cell Chem Biol</source>
        <volume>27</volume>
        <year>2020</year>
        <fpage>998</fpage>
        <lpage>1014</lpage>
        <pub-id pub-id-type="doi">10.1016/J.CHEMBIOL.2020.07.020</pub-id>
        <pub-id pub-id-type="pmid">32795419</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>13</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PROTACs: great opportunities for academia and industry</article-title>
        <source>Signal Transduct Target Ther</source>
        <year>2019</year>
        <fpage>4</fpage>
        <pub-id pub-id-type="doi">10.1038/S41392-019-0101-6</pub-id>
        <pub-id pub-id-type="pmid">30820356</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>14</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Cruz Walma</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Bullock</surname>
            <given-names>A.N.</given-names>
          </name>
          <name>
            <surname>Yamada</surname>
            <given-names>K.M.</given-names>
          </name>
        </person-group>
        <article-title>Ubiquitin ligases: guardians of mammalian development</article-title>
        <source>Nat Rev Mol Cell Biol</source>
        <year>2022</year>
        <fpage>0123456789</fpage>
        <pub-id pub-id-type="doi">10.1038/s41580-021-00448-5</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>15</label>
      <element-citation publication-type="journal" id="h0075">
        <person-group person-group-type="author">
          <name>
            <surname>Bateman</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Orchard</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Magrane</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Agivetova</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ahmad</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>UniProt: the universal protein knowledgebase in 2021</article-title>
        <source>Nucleic Acids Res</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D480</fpage>
        <lpage>D489</lpage>
        <pub-id pub-id-type="doi">10.1093/NAR/GKAA1100</pub-id>
        <pub-id pub-id-type="pmid">33237286</pub-id>
      </element-citation>
    </ref>
    <ref id="b0080">
      <label>16</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>Blum</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>H.Y.</given-names>
          </name>
          <name>
            <surname>Chuguransky</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Grego</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Kandasaamy</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Mitchell</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The InterPro protein families and domains database: 20 years on</article-title>
        <source>Nucleic Acids Res</source>
        <volume>49</volume>
        <year>2021</year>
        <fpage>D344</fpage>
        <lpage>D354</lpage>
        <pub-id pub-id-type="doi">10.1093/NAR/GKAA977</pub-id>
        <pub-id pub-id-type="pmid">33156333</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>17</label>
      <element-citation publication-type="journal" id="h0085">
        <person-group person-group-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>A.J.M.</given-names>
          </name>
          <name>
            <surname>Holliday</surname>
            <given-names>G.L.</given-names>
          </name>
          <name>
            <surname>Furnham</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Tyzack</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Ferris</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Thornton</surname>
            <given-names>J.M.</given-names>
          </name>
        </person-group>
        <article-title>Mechanism and Catalytic Site Atlas (M-CSA): a database of enzyme reaction mechanisms and active sites</article-title>
        <source>Nucleic Acids Res</source>
        <volume>46</volume>
        <year>2018</year>
        <fpage>D618</fpage>
        <lpage>D623</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1012</pub-id>
        <pub-id pub-id-type="pmid">29106569</pub-id>
      </element-citation>
    </ref>
    <ref id="b0090">
      <label>18</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Sheridan</surname>
            <given-names>R.P.</given-names>
          </name>
          <name>
            <surname>Maiorov</surname>
            <given-names>V.N.</given-names>
          </name>
          <name>
            <surname>Holloway</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Cornell</surname>
            <given-names>W.D.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>Y.D.</given-names>
          </name>
        </person-group>
        <article-title>Drug-like density: a method of quantifying the “bindability” of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank</article-title>
        <source>J Chem Inf Model</source>
        <volume>50</volume>
        <year>2010</year>
        <fpage>2029</fpage>
        <lpage>2040</lpage>
        <pub-id pub-id-type="doi">10.1021/CI100312T</pub-id>
        <pub-id pub-id-type="pmid">20977231</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>19</label>
      <element-citation publication-type="journal" id="h0095">
        <person-group person-group-type="author">
          <name>
            <surname>Backus</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Correia</surname>
            <given-names>B.E.</given-names>
          </name>
          <name>
            <surname>Lum</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Forli</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Horning</surname>
            <given-names>B.D.</given-names>
          </name>
          <name>
            <surname>González-Páez</surname>
            <given-names>G.E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteome-wide covalent ligand discovery in native biological systems</article-title>
        <source>Nature</source>
        <volume>534</volume>
        <year>2016</year>
        <fpage>570</fpage>
        <lpage>574</lpage>
        <pub-id pub-id-type="doi">10.1038/NATURE18002</pub-id>
        <pub-id pub-id-type="pmid">27309814</pub-id>
      </element-citation>
    </ref>
    <ref id="b0100">
      <label>20</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Chi</surname>
            <given-names>J. (Jack)</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Izquierdo-Ferrer</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xue</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wavelet</surname>
            <given-names>C.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A novel strategy to block mitotic progression for targeted therapy</article-title>
        <source>EBioMedicine</source>
        <volume>49</volume>
        <year>2019</year>
        <fpage>40</fpage>
        <lpage>54</lpage>
        <pub-id pub-id-type="doi">10.1016/J.EBIOM.2019.10.013</pub-id>
        <pub-id pub-id-type="pmid">31669221</pub-id>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>21</label>
      <element-citation publication-type="journal" id="h0105">
        <person-group person-group-type="author">
          <name>
            <surname>Simpson</surname>
            <given-names>G.L.</given-names>
          </name>
          <name>
            <surname>Bertrand</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Borthwick</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Campobasso</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Chabanet</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS Methodologies</article-title>
        <source>J Med Chem</source>
        <volume>62</volume>
        <year>2019</year>
        <fpage>2154</fpage>
        <lpage>2171</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.8B01872</pub-id>
        <pub-id pub-id-type="pmid">30689376</pub-id>
      </element-citation>
    </ref>
    <ref id="b0110">
      <label>22</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Perry</surname>
            <given-names>J.J.P.</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Moiani</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Tainer</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>p38α MAP Kinase C-Terminal Domain Binding Pocket Characterized by Crystallographic and Computational Analyses</article-title>
        <source>J Mol Biol</source>
        <volume>391</volume>
        <year>2009</year>
        <fpage>1</fpage>
        <lpage>11</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jmb.2009.06.005</pub-id>
        <pub-id pub-id-type="pmid">19501598</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>23</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Sadowsky</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Burlingame</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Wolan</surname>
            <given-names>D.W.</given-names>
          </name>
          <name>
            <surname>McClendon</surname>
            <given-names>C.L.</given-names>
          </name>
          <name>
            <surname>Jacobson</surname>
            <given-names>M.P.</given-names>
          </name>
          <name>
            <surname>Wells</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>Turning a protein kinase on or off from a single allosteric site via disulfide trapping</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <volume>108</volume>
        <year>2011</year>
        <fpage>6056</fpage>
        <lpage>6061</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1102376108</pub-id>
        <pub-id pub-id-type="pmid">21430264</pub-id>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>24</label>
      <element-citation publication-type="journal" id="h0120">
        <person-group person-group-type="author">
          <name>
            <surname>Wood</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Lopez-Fernandez</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Knight</surname>
            <given-names>L.E.</given-names>
          </name>
          <name>
            <surname>Al-Khawaldeh</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Gai</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>FragLites - Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation</article-title>
        <source>J Med Chem</source>
        <volume>62</volume>
        <year>2019</year>
        <fpage>3741</fpage>
        <lpage>3752</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.9B00304/SUPPL_FILE/JM9B00304_SI_003.PDF</pub-id>
        <pub-id pub-id-type="pmid">30860382</pub-id>
      </element-citation>
    </ref>
    <ref id="b0125">
      <label>25</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Edward Zhou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Novick</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Brunzelle</surname>
            <given-names>J.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Structures of AMP-activated protein kinase bound to novel pharmacological activators in phosphorylated, non-phosphorylated, and nucleotide-free states</article-title>
        <source>J Biol Chem</source>
        <volume>294</volume>
        <year>2019</year>
        <fpage>953</fpage>
        <lpage>967</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.RA118.004883</pub-id>
        <pub-id pub-id-type="pmid">30478170</pub-id>
      </element-citation>
    </ref>
    <ref id="b0130">
      <label>26</label>
      <element-citation publication-type="journal" id="h0130">
        <person-group person-group-type="author">
          <name>
            <surname>Hennings</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Blumberg</surname>
            <given-names>P.M.</given-names>
          </name>
          <name>
            <surname>Pettit</surname>
            <given-names>G.R.</given-names>
          </name>
          <name>
            <surname>Herald</surname>
            <given-names>C.L.</given-names>
          </name>
          <name>
            <surname>Shores</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Yuspa</surname>
            <given-names>S.H.</given-names>
          </name>
        </person-group>
        <article-title>Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin</article-title>
        <source>Carcinogenesis</source>
        <volume>8</volume>
        <year>1987</year>
        <fpage>1343</fpage>
        <lpage>1346</lpage>
        <pub-id pub-id-type="doi">10.1093/CARCIN/8.9.1343</pub-id>
        <pub-id pub-id-type="pmid">3621472</pub-id>
      </element-citation>
    </ref>
    <ref id="b0135">
      <label>27</label>
      <element-citation publication-type="journal" id="h0135">
        <person-group person-group-type="author">
          <name>
            <surname>Mach</surname>
            <given-names>U.R.</given-names>
          </name>
          <name>
            <surname>Lewin</surname>
            <given-names>N.E.</given-names>
          </name>
          <name>
            <surname>Blumberg</surname>
            <given-names>P.M.</given-names>
          </name>
          <name>
            <surname>Kozikowski</surname>
            <given-names>A.P.</given-names>
          </name>
        </person-group>
        <article-title>Synthesis and pharmacological evaluation of 8- and 9-substituted benzolactam-v8 derivatives as potent ligands for protein kinase C, a therapeutic target for Alzheimer’s disease</article-title>
        <source>ChemMedChem</source>
        <volume>1</volume>
        <year>2006</year>
        <fpage>307</fpage>
        <lpage>314</lpage>
        <pub-id pub-id-type="doi">10.1002/CMDC.200500068</pub-id>
        <pub-id pub-id-type="pmid">16892365</pub-id>
      </element-citation>
    </ref>
    <ref id="b0140">
      <label>28</label>
      <element-citation publication-type="journal" id="h0140">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Kazanietz</surname>
            <given-names>M.G.</given-names>
          </name>
          <name>
            <surname>Blumberg</surname>
            <given-names>P.M.</given-names>
          </name>
          <name>
            <surname>Hurley</surname>
            <given-names>J.H.</given-names>
          </name>
        </person-group>
        <article-title>Crystal Structure of the Cys2 Activator-Binding Domain of Protein Kinase C8 in Complex with Phorbol Ester</article-title>
        <source>Cell</source>
        <volume>81</volume>
        <year>1995</year>
        <fpage>917</fpage>
        <lpage>924</lpage>
        <pub-id pub-id-type="pmid">7781068</pub-id>
      </element-citation>
    </ref>
    <ref id="b0145">
      <label>29</label>
      <element-citation publication-type="journal" id="h0145">
        <person-group person-group-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mahen</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Rossmann</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Stokes</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Hardwick</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Huggins</surname>
            <given-names>D.J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation</article-title>
        <source>Sci Rep</source>
        <year>2019</year>
        <fpage>9</fpage>
        <pub-id pub-id-type="doi">10.1038/S41598-019-50702-2</pub-id>
        <pub-id pub-id-type="pmid">30626887</pub-id>
      </element-citation>
    </ref>
    <ref id="b0150">
      <label>30</label>
      <element-citation publication-type="journal" id="h0150">
        <person-group person-group-type="author">
          <name>
            <surname>Schapira</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tyers</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Torrent</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Arrowsmith</surname>
            <given-names>C.H.</given-names>
          </name>
        </person-group>
        <article-title>WD40 repeat domain proteins: a novel target class?</article-title>
        <source>Nat Rev Drug Discov</source>
        <volume>16</volume>
        <year>2017</year>
        <fpage>773</fpage>
        <lpage>786</lpage>
        <pub-id pub-id-type="doi">10.1038/NRD.2017.179</pub-id>
        <pub-id pub-id-type="pmid">29026209</pub-id>
      </element-citation>
    </ref>
    <ref id="b0155">
      <label>31</label>
      <element-citation publication-type="journal" id="h0155">
        <person-group person-group-type="author">
          <name>
            <surname>Kozlyuk</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Gilston</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Salay</surname>
            <given-names>L.E.</given-names>
          </name>
          <name>
            <surname>Gogliotti</surname>
            <given-names>R.D.</given-names>
          </name>
          <name>
            <surname>Christov</surname>
            <given-names>P.P.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A fragment-based approach to discovery of Receptor for Advanced Glycation End products inhibitors</article-title>
        <source>Proteins</source>
        <volume>89</volume>
        <year>2021</year>
        <fpage>1399</fpage>
        <lpage>1412</lpage>
        <pub-id pub-id-type="doi">10.1002/PROT.26162</pub-id>
        <pub-id pub-id-type="pmid">34156100</pub-id>
      </element-citation>
    </ref>
    <ref id="b0160">
      <label>32</label>
      <element-citation publication-type="journal" id="h0160">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Mao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xiong</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>You</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain</article-title>
        <source>Angew Chem Int Ed Engl</source>
        <volume>60</volume>
        <year>2021</year>
        <fpage>8760</fpage>
        <lpage>8765</lpage>
        <pub-id pub-id-type="doi">10.1002/ANIE.202017200</pub-id>
        <pub-id pub-id-type="pmid">33511756</pub-id>
      </element-citation>
    </ref>
    <ref id="b0165">
      <label>33</label>
      <element-citation publication-type="journal" id="h0165">
        <person-group person-group-type="author">
          <name>
            <surname>Tautermann</surname>
            <given-names>C.S.</given-names>
          </name>
          <name>
            <surname>Binder</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Büttner</surname>
            <given-names>F.H.</given-names>
          </name>
          <name>
            <surname>Eickmeier</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Fiegen</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>U.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Allosteric Activation of Striatal-Enriched Protein Tyrosine Phosphatase (STEP, PTPN5) by a Fragment-like Molecule</article-title>
        <source>J Med Chem</source>
        <volume>62</volume>
        <year>2019</year>
        <fpage>306</fpage>
        <lpage>316</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.8B00857</pub-id>
        <pub-id pub-id-type="pmid">30207464</pub-id>
      </element-citation>
    </ref>
    <ref id="b0170">
      <label>34</label>
      <element-citation publication-type="journal" id="h0170">
        <person-group person-group-type="author">
          <name>
            <surname>Leonard</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Izadmehr</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>O’Connor</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Wiredja</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Selective PP2A Enhancement through Biased Heterotrimer Stabilization</article-title>
        <source>Cell</source>
        <volume>181</volume>
        <year>2020</year>
        <fpage>688</fpage>
        <lpage>701.e16</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2020.03.038</pub-id>
        <pub-id pub-id-type="pmid">32315618</pub-id>
      </element-citation>
    </ref>
    <ref id="b0175">
      <label>35</label>
      <element-citation publication-type="journal" id="h0175">
        <person-group person-group-type="author">
          <name>
            <surname>Doyle</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Sheng</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>MacKinnon</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ</article-title>
        <source>Cell</source>
        <volume>85</volume>
        <year>1996</year>
        <fpage>1067</fpage>
        <lpage>1076</lpage>
        <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81307-0</pub-id>
        <pub-id pub-id-type="pmid">8674113</pub-id>
      </element-citation>
    </ref>
    <ref id="b0180">
      <label>36</label>
      <element-citation publication-type="journal" id="h0180">
        <person-group person-group-type="author">
          <name>
            <surname>Genera</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Samson</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Raynal</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Haouz</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Baron</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Simenel</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Structural and functional characterization of the PDZ domain of the human phosphatase PTPN3 and its interaction with the human papillomavirus E6 oncoprotein</article-title>
        <source>Sci Rep</source>
        <volume>9</volume>
        <year>2019</year>
        <pub-id pub-id-type="doi">10.1038/S41598-019-43932-X</pub-id>
      </element-citation>
    </ref>
    <ref id="b0185">
      <label>37</label>
      <element-citation publication-type="journal" id="h0185">
        <person-group person-group-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>E.Y.S.</given-names>
          </name>
          <name>
            <surname>Silvian</surname>
            <given-names>L.F.</given-names>
          </name>
          <name>
            <surname>Marcotte</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Banos</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Jow</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>T.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Potent PDZ-Domain PICK1 Inhibitors that Modulate Amyloid Beta-Mediated Synaptic Dysfunction</article-title>
        <source>Sci Rep</source>
        <volume>8</volume>
        <year>2018</year>
        <pub-id pub-id-type="doi">10.1038/S41598-018-31680-3</pub-id>
      </element-citation>
    </ref>
    <ref id="b0190">
      <label>38</label>
      <element-citation publication-type="journal" id="h0190">
        <person-group person-group-type="author">
          <name>
            <surname>Böttcher</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Dilworth</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Reiser</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Neumüller</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Schleicher</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Petronczki</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3</article-title>
        <source>Nat Chem Biol</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>822</fpage>
        <lpage>829</lpage>
        <pub-id pub-id-type="doi">10.1038/S41589-019-0310-X</pub-id>
        <pub-id pub-id-type="pmid">31285596</pub-id>
      </element-citation>
    </ref>
    <ref id="b0195">
      <label>39</label>
      <element-citation publication-type="journal" id="h0195">
        <person-group person-group-type="author">
          <name>
            <surname>Dilworth</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hanley</surname>
            <given-names>R.P.</given-names>
          </name>
          <name>
            <surname>Ferreira de Freitas</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Allali-Hassani</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mehta</surname>
            <given-names>N.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization</article-title>
        <source>Nat Chem Biol</source>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.1038/S41589-021-00898-0</pub-id>
      </element-citation>
    </ref>
    <ref id="b0200">
      <label>40</label>
      <element-citation publication-type="journal" id="h0200">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>K.-S.</given-names>
          </name>
          <name>
            <surname>Storey</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Tsai</surname>
            <given-names>Y.-H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells</article-title>
        <source>Cell Chem Biol</source>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.1016/J.CHEMBIOL.2021.08.004</pub-id>
      </element-citation>
    </ref>
    <ref id="b0205">
      <label>41</label>
      <element-citation publication-type="journal" id="h0205">
        <person-group person-group-type="author">
          <name>
            <surname>Keats</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Reiman</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Maxwell</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Larratt</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Mant</surname>
            <given-names>M.J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression</article-title>
        <source>Blood</source>
        <volume>101</volume>
        <year>2003</year>
        <fpage>1520</fpage>
        <lpage>1529</lpage>
        <pub-id pub-id-type="doi">10.1182/BLOOD-2002-06-1675</pub-id>
        <pub-id pub-id-type="pmid">12393535</pub-id>
      </element-citation>
    </ref>
    <ref id="b0210">
      <label>42</label>
      <element-citation publication-type="journal" id="h0210">
        <person-group person-group-type="author">
          <name>
            <surname>Yuan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Flores</surname>
            <given-names>N.M.</given-names>
          </name>
          <name>
            <surname>Hausmann</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lofgren</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Kharchenko</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Angulo-Ibanez</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Elevated NSD3 histone methylation activity drives squamous cell lung cancer</article-title>
        <source>Nature</source>
        <volume>590</volume>
        <year>2021</year>
        <fpage>504</fpage>
        <lpage>508</lpage>
        <pub-id pub-id-type="doi">10.1038/S41586-020-03170-Y</pub-id>
        <pub-id pub-id-type="pmid">33536620</pub-id>
      </element-citation>
    </ref>
    <ref id="b0215">
      <label>43</label>
      <element-citation publication-type="journal" id="h0215">
        <person-group person-group-type="author">
          <name>
            <surname>Rodriguez-Paredes</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Martinez De Paz</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Simó-Riudalbas</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Sayols</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Moutinho</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Moran</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis</article-title>
        <source>Oncogene</source>
        <volume>33</volume>
        <year>2014</year>
        <fpage>2807</fpage>
        <lpage>2813</lpage>
        <pub-id pub-id-type="doi">10.1038/ONC.2013.239</pub-id>
        <pub-id pub-id-type="pmid">23770855</pub-id>
      </element-citation>
    </ref>
    <ref id="b0220">
      <label>44</label>
      <element-citation publication-type="journal" id="h0220">
        <person-group person-group-type="author">
          <name>
            <surname>Sengupta</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Hausmann</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ghosh</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis</article-title>
        <source>Mol Cell</source>
        <volume>81</volume>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.1016/J.MOLCEL.2021.08.034</pub-id>
      </element-citation>
    </ref>
    <ref id="b0225">
      <label>45</label>
      <element-citation publication-type="journal" id="h0225">
        <person-group person-group-type="author">
          <name>
            <surname>Filippakopoulos</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Knapp</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Targeting bromodomains: epigenetic readers of lysine acetylation</article-title>
        <source>Nat Rev Drug Discov</source>
        <volume>13</volume>
        <year>2014</year>
        <fpage>337</fpage>
        <lpage>356</lpage>
        <pub-id pub-id-type="doi">10.1038/NRD4286</pub-id>
        <pub-id pub-id-type="pmid">24751816</pub-id>
      </element-citation>
    </ref>
    <ref id="b0230">
      <label>46</label>
      <element-citation publication-type="journal" id="h0230">
        <person-group person-group-type="author">
          <name>
            <surname>Upadhyay</surname>
            <given-names>A.K.</given-names>
          </name>
          <name>
            <surname>Judge</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Pithawalla</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Simanis</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bodelle</surname>
            <given-names>P.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach</article-title>
        <source>Bioorg Med Chem Lett</source>
        <volume>28</volume>
        <year>2018</year>
        <fpage>1708</fpage>
        <lpage>1713</lpage>
        <pub-id pub-id-type="doi">10.1016/J.BMCL.2018.04.050</pub-id>
        <pub-id pub-id-type="pmid">29691138</pub-id>
      </element-citation>
    </ref>
    <ref id="b0235">
      <label>47</label>
      <element-citation publication-type="journal" id="h0235">
        <person-group person-group-type="author">
          <name>
            <surname>Verdin</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Ott</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond</article-title>
        <source>Nat Rev Mol Cell Biol</source>
        <volume>16</volume>
        <year>2015</year>
        <fpage>258</fpage>
        <lpage>264</lpage>
        <pub-id pub-id-type="doi">10.1038/NRM3931</pub-id>
        <pub-id pub-id-type="pmid">25549891</pub-id>
      </element-citation>
    </ref>
    <ref id="b0240">
      <label>48</label>
      <element-citation publication-type="journal" id="h0240">
        <person-group person-group-type="author">
          <name>
            <surname>Choudhary</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Gnad</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Rehman</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Walther</surname>
            <given-names>T.C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Lysine acetylation targets protein complexes and co-regulates major cellular functions</article-title>
        <source>Science</source>
        <volume>325</volume>
        <year>2009</year>
        <fpage>834</fpage>
        <lpage>840</lpage>
        <pub-id pub-id-type="doi">10.1126/SCIENCE.1175371</pub-id>
        <pub-id pub-id-type="pmid">19608861</pub-id>
      </element-citation>
    </ref>
    <ref id="b0245">
      <label>49</label>
      <element-citation publication-type="journal" id="h0245">
        <person-group person-group-type="author">
          <name>
            <surname>Song</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z.D.</given-names>
          </name>
          <name>
            <surname>Schapira</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Disease Association and Druggability of WD40 Repeat Proteins</article-title>
        <source>J Proteome Res</source>
        <volume>16</volume>
        <year>2017</year>
        <fpage>3766</fpage>
        <lpage>3773</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JPROTEOME.7B00451</pub-id>
        <pub-id pub-id-type="pmid">28956604</pub-id>
      </element-citation>
    </ref>
    <ref id="b0250">
      <label>50</label>
      <element-citation publication-type="journal" id="h0250">
        <person-group person-group-type="author">
          <name>
            <surname>Ferreira De Freitas</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Harding</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Franzoni</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Ravichandran</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mann</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors</article-title>
        <source>J Med Chem</source>
        <volume>61</volume>
        <year>2018</year>
        <fpage>4517</fpage>
        <lpage>4527</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.8B00258</pub-id>
        <pub-id pub-id-type="pmid">29741882</pub-id>
      </element-citation>
    </ref>
    <ref id="b0255">
      <label>51</label>
      <element-citation publication-type="journal" id="h0255">
        <person-group person-group-type="author">
          <name>
            <surname>Mann</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Franzoni</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>De Freitas</surname>
            <given-names>R.F.</given-names>
          </name>
          <name>
            <surname>Tempel</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Houliston</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Discovery of Small Molecule Antagonists of the USP5 Zinc Finger Ubiquitin-Binding Domain</article-title>
        <source>J Med Chem</source>
        <volume>62</volume>
        <year>2019</year>
        <fpage>10144</fpage>
        <lpage>10155</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.9B00988</pub-id>
        <pub-id pub-id-type="pmid">31663737</pub-id>
      </element-citation>
    </ref>
    <ref id="b0260">
      <label>52</label>
      <element-citation publication-type="journal" id="h0260">
        <person-group person-group-type="author">
          <name>
            <surname>Faesen</surname>
            <given-names>A.C.</given-names>
          </name>
          <name>
            <surname>Dirac</surname>
            <given-names>A.M.G.</given-names>
          </name>
          <name>
            <surname>Shanmugham</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ovaa</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Perrakis</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sixma</surname>
            <given-names>T.K.</given-names>
          </name>
        </person-group>
        <article-title>Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase</article-title>
        <source>Mol Cell</source>
        <volume>44</volume>
        <year>2011</year>
        <fpage>147</fpage>
        <lpage>159</lpage>
        <pub-id pub-id-type="doi">10.1016/J.MOLCEL.2011.06.034</pub-id>
        <pub-id pub-id-type="pmid">21981925</pub-id>
      </element-citation>
    </ref>
    <ref id="b0265">
      <label>53</label>
      <element-citation publication-type="journal" id="h0265">
        <person-group person-group-type="author">
          <name>
            <surname>Reily</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>T.J.</given-names>
          </name>
          <name>
            <surname>Renfrow</surname>
            <given-names>M.B.</given-names>
          </name>
          <name>
            <surname>Novak</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Glycosylation in health and disease</article-title>
        <source>Nat Rev Nephrol</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>346</fpage>
        <lpage>366</lpage>
        <pub-id pub-id-type="doi">10.1038/S41581-019-0129-4</pub-id>
        <pub-id pub-id-type="pmid">30858582</pub-id>
      </element-citation>
    </ref>
    <ref id="b0270">
      <label>54</label>
      <element-citation publication-type="journal" id="h0270">
        <person-group person-group-type="author">
          <name>
            <surname>Ramirez</surname>
            <given-names>D.H.</given-names>
          </name>
          <name>
            <surname>Aonbangkhen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>H.Y.</given-names>
          </name>
          <name>
            <surname>Naftaly</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>O’Meara</surname>
            <given-names>T.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Engineering a Proximity-Directed O-GlcNAc Transferase for Selective Protein O-GlcNAcylation in Cells</article-title>
        <source>ACS Chem Biol</source>
        <volume>15</volume>
        <year>2020</year>
        <fpage>1059</fpage>
        <lpage>1066</lpage>
        <pub-id pub-id-type="doi">10.1021/ACSCHEMBIO.0C00074</pub-id>
        <pub-id pub-id-type="pmid">32119511</pub-id>
      </element-citation>
    </ref>
    <ref id="b0275">
      <label>55</label>
      <element-citation publication-type="journal" id="h0275">
        <person-group person-group-type="author">
          <name>
            <surname>Ferreira De Freitas</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Szewczyk</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Mehta</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>McLeod</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2</article-title>
        <source>J Med Chem</source>
        <volume>64</volume>
        <year>2021</year>
        <fpage>1584</fpage>
        <lpage>1592</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.0C01768</pub-id>
        <pub-id pub-id-type="pmid">33522809</pub-id>
      </element-citation>
    </ref>
    <ref id="b0280">
      <label>56</label>
      <element-citation publication-type="journal" id="h0280">
        <person-group person-group-type="author">
          <name>
            <surname>Harding</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Ferreira De Freitas</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Franzoni</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Ravichandran</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin</article-title>
        <source>J Med Chem</source>
        <volume>60</volume>
        <year>2017</year>
        <fpage>9090</fpage>
        <lpage>9096</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JMEDCHEM.7B00933/SUPPL_FILE/JM7B00933_SI_012.CSV</pub-id>
        <pub-id pub-id-type="pmid">29019676</pub-id>
      </element-citation>
    </ref>
    <ref id="b0285">
      <label>57</label>
      <element-citation publication-type="journal" id="h0285">
        <person-group person-group-type="author">
          <name>
            <surname>Ge</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ramirez</surname>
            <given-names>D.H.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>D’Souza</surname>
            <given-names>A.K.</given-names>
          </name>
          <name>
            <surname>Aonbangkhen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase</article-title>
        <source>Nat Chem Biol</source>
        <volume>17</volume>
        <year>2021</year>
        <fpage>593</fpage>
        <lpage>600</lpage>
        <pub-id pub-id-type="doi">10.1038/S41589-021-00757-Y</pub-id>
        <pub-id pub-id-type="pmid">33686291</pub-id>
      </element-citation>
    </ref>
    <ref id="b0290">
      <label>58</label>
      <element-citation publication-type="journal" id="h0290">
        <person-group person-group-type="author">
          <name>
            <surname>Xiao</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Woods</surname>
            <given-names>E.C.</given-names>
          </name>
          <name>
            <surname>Vukojicic</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Bertozzi</surname>
            <given-names>C.R.</given-names>
          </name>
        </person-group>
        <article-title>Precision glycocalyx editing as a strategy for cancer immunotherapy</article-title>
        <source>Proc Natl Acad Sci U S A</source>
        <volume>113</volume>
        <year>2016</year>
        <fpage>10304</fpage>
        <lpage>10309</lpage>
        <pub-id pub-id-type="doi">10.1073/PNAS.1608069113</pub-id>
        <pub-id pub-id-type="pmid">27551071</pub-id>
      </element-citation>
    </ref>
    <ref id="b0295">
      <label>59</label>
      <element-citation publication-type="journal" id="h0295">
        <person-group person-group-type="author">
          <name>
            <surname>Gray</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Stanczak</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Mantuano</surname>
            <given-names>N.R.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Pijnenborg</surname>
            <given-names>J.F.A.</given-names>
          </name>
          <name>
            <surname>Malaker</surname>
            <given-names>S.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Targeted glycan degradation potentiates the anticancer immune response in vivo</article-title>
        <source>Nat Chem Biol</source>
        <volume>16</volume>
        <year>2020</year>
        <fpage>1376</fpage>
        <lpage>1384</lpage>
        <pub-id pub-id-type="doi">10.1038/s41589-020-0622-x</pub-id>
        <pub-id pub-id-type="pmid">32807964</pub-id>
      </element-citation>
    </ref>
    <ref id="b0300">
      <label>60</label>
      <element-citation publication-type="journal" id="h0300">
        <person-group person-group-type="author">
          <name>
            <surname>Ward</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Kleinman</surname>
            <given-names>J.I.</given-names>
          </name>
          <name>
            <surname>Brittain</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>P.S.</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>C.Y.S.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications</article-title>
        <source>ACS Chem Biol</source>
        <volume>14</volume>
        <year>2019</year>
        <fpage>2430</fpage>
        <lpage>2440</lpage>
        <pub-id pub-id-type="doi">10.1021/ACSCHEMBIO.8B01083</pub-id>
        <pub-id pub-id-type="pmid">31059647</pub-id>
      </element-citation>
    </ref>
    <ref id="b0305">
      <label>61</label>
      <element-citation publication-type="journal" id="h0305">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Crowley</surname>
            <given-names>V.M.</given-names>
          </name>
          <name>
            <surname>Wucherpfennig</surname>
            <given-names>T.G.</given-names>
          </name>
          <name>
            <surname>Dix</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Cravatt</surname>
            <given-names>B.F.</given-names>
          </name>
        </person-group>
        <article-title>Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16</article-title>
        <source>Nat Chem Biol</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>737</fpage>
        <lpage>746</lpage>
        <pub-id pub-id-type="doi">10.1038/S41589-019-0279-5</pub-id>
        <pub-id pub-id-type="pmid">31209349</pub-id>
      </element-citation>
    </ref>
    <ref id="b0310">
      <label>62</label>
      <element-citation publication-type="journal" id="h0310">
        <person-group person-group-type="author">
          <name>
            <surname>Spradlin</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ward</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Brittain</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>Ou</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Harnessing the anti-cancer natural product nimbolide for targeted protein degradation</article-title>
        <source>Nat Chem Biol</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>747</fpage>
        <lpage>755</lpage>
        <pub-id pub-id-type="doi">10.1038/S41589-019-0304-8</pub-id>
        <pub-id pub-id-type="pmid">31209351</pub-id>
      </element-citation>
    </ref>
    <ref id="b0315">
      <label>63</label>
      <element-citation publication-type="journal" id="h0315">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Spradlin</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Boike</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Brittain</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>McKenna</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function</article-title>
        <source>Cell Chem Biol</source>
        <volume>28</volume>
        <year>2021</year>
        <fpage>559</fpage>
        <lpage>566.e15</lpage>
        <pub-id pub-id-type="doi">10.1016/J.CHEMBIOL.2021.01.005</pub-id>
        <pub-id pub-id-type="pmid">33513350</pub-id>
      </element-citation>
    </ref>
    <ref id="b0320">
      <label>64</label>
      <element-citation publication-type="journal" id="h0320">
        <person-group person-group-type="author">
          <name>
            <surname>Tong</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Spradlin</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Tallarico</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>McKenna</surname>
            <given-names>J.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Bardoxolone conjugation enables targeted protein degradation of BRD4</article-title>
        <source>Sci Rep</source>
        <volume>10</volume>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1038/S41598-020-72491-9</pub-id>
      </element-citation>
    </ref>
    <ref id="b0325">
      <label>65</label>
      <element-citation publication-type="journal" id="h0325">
        <person-group person-group-type="author">
          <name>
            <surname>He</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Selvaraju</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Curtin</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Jakob</surname>
            <given-names>C.G.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Comess</surname>
            <given-names>K.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex</article-title>
        <source>Nat Chem Biol</source>
        <volume>134</volume>
        <issue>13</issue>
        <year>2017</year>
        <fpage>389</fpage>
        <lpage>395</lpage>
        <pub-id pub-id-type="doi">10.1038/nchembio.2306</pub-id>
      </element-citation>
    </ref>
    <ref id="b0330">
      <label>66</label>
      <element-citation publication-type="journal" id="h0330">
        <person-group person-group-type="author">
          <name>
            <surname>Qi</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED</article-title>
        <source>Nat Chem Biol</source>
        <volume>134</volume>
        <issue>13</issue>
        <year>2017</year>
        <fpage>381</fpage>
        <lpage>388</lpage>
        <pub-id pub-id-type="doi">10.1038/nchembio.2304</pub-id>
      </element-citation>
    </ref>
    <ref id="b0335">
      <label>67</label>
      <element-citation publication-type="journal" id="h0335">
        <person-group person-group-type="author">
          <name>
            <surname>Grebien</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Vedadi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Getlik</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Giambruno</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Grover</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Avellino</surname>
            <given-names>R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia</article-title>
        <source>Nat Chem Biol</source>
        <volume>118</volume>
        <issue>11</issue>
        <year>2015</year>
        <fpage>571</fpage>
        <lpage>578</lpage>
        <pub-id pub-id-type="doi">10.1038/nchembio.1859</pub-id>
      </element-citation>
    </ref>
    <ref id="b0340">
      <label>68</label>
      <element-citation publication-type="journal" id="h0340">
        <person-group person-group-type="author">
          <name>
            <surname>Varadi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Anyango</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Deshpande</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Nair</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Natassia</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Yordanova</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title>
        <source>Nucleic Acids Res</source>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.1093/NAR/GKAB1061</pub-id>
      </element-citation>
    </ref>
    <ref id="b0345">
      <label>69</label>
      <element-citation publication-type="journal" id="h0345">
        <person-group person-group-type="author">
          <name>
            <surname>Jumper</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pritzel</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Figurnov</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ronneberger</surname>
            <given-names>O.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Highly accurate protein structure prediction with AlphaFold</article-title>
        <source>Nat</source>
        <volume>596</volume>
        <year>2021</year>
        <fpage>583</fpage>
        <lpage>589</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>
      </element-citation>
    </ref>
    <ref id="b0350">
      <label>70</label>
      <element-citation publication-type="journal" id="h0350">
        <person-group person-group-type="author">
          <name>
            <surname>Baek</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>DiMaio</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Anishchenko</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Dauparas</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ovchinnikov</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>G.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Accurate prediction of protein structures and interactions using a three-track neural network</article-title>
        <source>Science (80-)</source>
        <volume>373</volume>
        <year>2021</year>
        <fpage>871</fpage>
        <lpage>876</lpage>
        <pub-id pub-id-type="doi">10.1126/SCIENCE.ABJ8754/SUPPL_FILE/ABJ8754_MDAR_REPRODUCIBILITY_CHECKLIST.PDF</pub-id>
      </element-citation>
    </ref>
    <ref id="b0355">
      <label>71</label>
      <element-citation publication-type="journal" id="h0355">
        <person-group person-group-type="author">
          <name>
            <surname>Drummond</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>C.I.</given-names>
          </name>
        </person-group>
        <article-title>In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application</article-title>
        <source>J Chem Inf Model</source>
        <volume>59</volume>
        <year>2019</year>
        <fpage>1634</fpage>
        <lpage>1644</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JCIM.8B00872/SUPPL_FILE/CI8B00872_SI_001.PDF</pub-id>
        <pub-id pub-id-type="pmid">30714732</pub-id>
      </element-citation>
    </ref>
    <ref id="b0360">
      <label>72</label>
      <element-citation publication-type="journal" id="h0360">
        <person-group person-group-type="author">
          <name>
            <surname>Drummond</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Henry</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>C.I.</given-names>
          </name>
        </person-group>
        <article-title>Improved accuracy for modeling ProTAC-mediated ternary complex formation and targeted protein degradation via new in silico methodologies</article-title>
        <source>J Chem Inf Model</source>
        <volume>60</volume>
        <year>2020</year>
        <fpage>5234</fpage>
        <lpage>5254</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JCIM.0C00897/SUPPL_FILE/CI0C00897_SI_001.PDF</pub-id>
        <pub-id pub-id-type="pmid">32969649</pub-id>
      </element-citation>
    </ref>
    <ref id="b0365">
      <label>73</label>
      <element-citation publication-type="journal" id="h0365">
        <person-group person-group-type="author">
          <name>
            <surname>Zaidman</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Prilusky</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>London</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes</article-title>
        <source>J Chem Inf Model</source>
        <volume>60</volume>
        <year>2020</year>
        <fpage>4894</fpage>
        <lpage>4903</lpage>
        <pub-id pub-id-type="doi">10.1021/ACS.JCIM.0C00589/SUPPL_FILE/CI0C00589_SI_001.PDF</pub-id>
        <pub-id pub-id-type="pmid">32976709</pub-id>
      </element-citation>
    </ref>
    <ref id="b0370">
      <label>74</label>
      <mixed-citation publication-type="other" id="h0370">Dixon T, MacPherson D, Mostofian B, Dauzhenka T, Lotz S, McGee D, et al. Atomic-Resolution Prediction of Degrader-mediated Ternary Complex Structures by Combining Molecular Simulations with Hydrogen Deuterium Exchange. <italic>BioRxiv</italic> 2021:2021.09.26.461830.</mixed-citation>
    </ref>
    <ref id="b0375">
      <label>75</label>
      <element-citation publication-type="journal" id="h0375">
        <person-group person-group-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Nie</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Unarta</surname>
            <given-names>I.C.</given-names>
          </name>
          <name>
            <surname>Ericksen</surname>
            <given-names>S.S.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>In Silico Modeling and Scoring of PROTAC-Mediated Ternary Complex Poses</article-title>
        <source>J Med Chem</source>
        <year>2022</year>
        <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02155</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="s0120" sec-type="supplementary-material">
    <label>Appendix A</label>
    <title>Supplementary data</title>
    <p id="p0210">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0010"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.docx"/></supplementary-material></p>
    <p id="p0215">
      <supplementary-material content-type="local-data" id="m0005">
        <caption>
          <title>Supplementary data 2</title>
        </caption>
        <media xlink:href="mmc2.csv"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ak005">
    <sec id="s0105">
      <title>Acknowledgements</title>
      <p id="p0195">This research was enabled in part by support provided by Compute Ontario (<ext-link ext-link-type="uri" xlink:href="https://www.computeontario.ca/" id="ir010">https://www.computeontario.ca/</ext-link>) and the Digital Research Alliance of Canada (alliancecan.ca).</p>
    </sec>
    <sec id="s0110">
      <title>Funding</title>
      <p id="p0200">MS gratefully acknowledges support from <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000038</institution-id><institution>NSERC</institution></institution-wrap></funding-source> [Grant RGPIN-2019-04416], CQDM (Quantum Leap-176) and MITACS accelerate (IT13051). The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Pfizer and Takeda.</p>
    </sec>
  </ack>
  <fn-group>
    <fn id="s0115" fn-type="supplementary-material">
      <label>Appendix A</label>
      <p id="p0205">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.csbj.2022.11.010" id="ir015">https://doi.org/10.1016/j.csbj.2022.11.010</ext-link>.</p>
    </fn>
  </fn-group>
</back>
